Siegbahn A, Venge P, Nilsson K
Scand J Haematol. 1983 Aug;31(2):184-92. doi: 10.1111/j.1600-0609.1983.tb01528.x.
In a previous study, we demonstrated the existence in serum from patients with chronic lymphocytic leukaemia (CLL) of a cell-directed, heat-labile chemokinetic inhibitor of polymorphonuclear leucocytes (PMN). The aim of this investigation was to study the cellular origin of this inhibitor. Supernatants from short term cultured lymphocytes from 3 healthy persons and 5 patients with CLL, and from 16 different established human non-haematopoietic and haematopoietic cell lines were analyzed. Only the leukaemic B-lymphocytes from the CLL patients produced the inhibitor. The presence of the inhibitor was also demonstrated in supernatants from the fresh CLL cells from one CLL patient and a leukaemic cell line established from these cells using Epstein-Barr virus as the immortalizing agent. A lymphoblastoid cell line derived from the normal B-cells of the same CLL patient did not produce the chemokinetic inhibitor. We therefore conclude that the cellular origin of the heat-labile, cell-directed chemokinetic inhibitor of PMN migration is the CLL cell.
在之前的一项研究中,我们证明了慢性淋巴细胞白血病(CLL)患者血清中存在一种针对细胞的、不耐热的多形核白细胞(PMN)化学趋化抑制剂。本研究的目的是探究这种抑制剂的细胞来源。分析了3名健康人和5名CLL患者短期培养淋巴细胞的上清液,以及16种不同的已建立的人类非造血和造血细胞系的上清液。只有CLL患者的白血病B淋巴细胞产生这种抑制剂。在一名CLL患者的新鲜CLL细胞以及使用爱泼斯坦-巴尔病毒作为永生化剂从这些细胞建立的白血病细胞系的上清液中也证实了抑制剂的存在。源自同一CLL患者正常B细胞的淋巴母细胞系不产生化学趋化抑制剂。因此,我们得出结论,PMN迁移的不耐热、针对细胞的化学趋化抑制剂的细胞来源是CLL细胞。